Laboratory of Animal Genetic Engineering and Stem Cell Biology, Subtropical/Tropical Organism Gene Bank, Jeju National University, Jeju, Republic of Korea.
Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Faculty of Biotechnology, Jeju National University, Jeju, Republic of Korea.
Cell Death Dis. 2018 Feb 14;9(2):244. doi: 10.1038/s41419-018-0277-7.
Chemotherapy is a standard treatment for non-small-cell lung cancer (NSCLC). However, the dose-limiting toxicity of drugs and the development of chemoresistance are major clinical challenges to successful management of NSCLC. Asian traditional medicine is gaining global attention as a non-toxic alternative to chemotherapy. BRM270 is an extract formulated from seven Asian medicinal plants that has been shown to inhibit tumor cell proliferation in diverse cancer types. We previously demonstrated that BRM270 suppresses tumorigenesis by negatively regulating nuclear factor-κB signaling in multidrug-resistant cancer stem cells (CSCs). In this study we report that the growth, migration, and invasion of normal human lung adenocarcinoma cells and their chemoresistant derivatives was inhibited by BRM270 treatment. Notably, BRM270 was found to modulate CSC self-renewal and tumor-initiating capacity via positive regulation of the miRNA-128. Thus, combination therapy with miRNA-128 and BRM270 may be an effective treatment strategy for chemoresistant NSCLC.
化疗是治疗非小细胞肺癌（NSCLC）的标准方法。然而，药物的剂量限制毒性和化疗耐药性的发展是成功治疗 NSCLC 的主要临床挑战。亚洲传统医学作为化疗的无毒替代方法正受到全球关注。BRM270 是一种从七种亚洲药用植物中提取的制剂，已被证明可抑制多种癌症类型的肿瘤细胞增殖。我们之前的研究表明，BRM270 通过负向调节多药耐药性肿瘤干细胞（CSC）中的核因子-κB 信号通路来抑制肿瘤发生。在这项研究中，我们报告 BRM270 处理可抑制正常人类肺腺癌细胞及其耐药衍生物的生长、迁移和侵袭。值得注意的是，发现 BRM270 通过正向调节 miRNA-128 来调节 CSC 自我更新和肿瘤起始能力。因此，miRNA-128 和 BRM270 的联合治疗可能是治疗耐药性 NSCLC 的有效治疗策略。
